DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge

Modified vaccinia Ankara (MVA) is being tested in humans as an alternative to the current smallpox vaccine Dryvax. Here, we compare the magnitude and longevity of protective immune responses elicited by a DNA/MVA HIV-1 vaccine with those elicited by Dryvax using a monkeypox virus/macaque model. The...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Nigam, Pragati, Earl, Patricia L., Americo, Jeffrey L., Sharma, Sunita, Wyatt, Linda S., Edghill-Spano, Yvette, Chennareddi, Lakshmi S., Silvera, Peter, Moss, Bernard, Robinson, Harriet L., Amara, Rama Rao
Format: Artigo
Langue:Inglês
Publié: Elsevier Inc. 2007
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2072046/
https://ncbi.nlm.nih.gov/pubmed/17507071
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.virol.2007.04.010
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires